Fifty years ago, it sounded unthinkable. Even a decade ago, it seemed like a fantasy. But in 2022, the use of psychoactive chemicals for therapeutic purposes is finally gaining traction. That movement is worth pondering for the design of future mental health benefits.
A winding down of the War on Drugs and gradual reconsideration of controlled substances’ place in society has allowed commercial and private re-examination of their use. It has also encouraged scientific and mental health professionals to study the efficacy of psychedelics such as ketamine, MDMA and psilocybin in the treatment of depression and other mental health conditions.
